IL6R and rheumatoid arthritis: Tocilizumab, the commercial name of anti-IL-6R antibodies, was approved for treatment of rheumatoid arthritis in 2012, and evidence has been collected for its beneficial effects on other systemic autoimmune diseases, including systemic lupus erythematosus, systemic sclerosis, polymyositis and large-vessel vasculitis [104,105].